Treatment with an IL6-neutralizing antibody completely eliminated chemoresistance of ovarian and lung cancer stem cells in vivo [196,197], suggesting that targeting IL-6 could be an effective strategy in eliminating bCSCs as well. The gene discussed is IL6; the disease is lung cancer.